Lipocine Inc. (LPCN)
NASDAQ: LPCN · IEX Real-Time Price · USD
5.05
+0.13 (2.64%)
May 7, 2024, 3:01 PM EDT - Market open
Lipocine Revenue
In the year 2023, Lipocine had annual revenue of $-2.85M, a decrease of -670.16%. Revenue in the quarter ending December 31, 2023 was $216.19K.
Revenue (ttm)
$-2.85M
Revenue Growth
-670.16%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
17
Market Cap
26.84M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | -2.85M | -3.35M | -670.16% |
Dec 31, 2022 | 500.00K | -15.64M | -96.90% |
Dec 31, 2021 | 16.14M | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 164.99K | -263.04K | -61.45% |
Dec 31, 2018 | 428.03K | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 7.71M | - | - |
Dec 31, 2011 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Exagen | 52.55M |
Qilian International Holding Group | 46.47M |
Marpai | 37.16M |
bioAffinity Technologies | 2.53M |
Oncternal Therapeutics | 785.00K |
Bullfrog AI | 65.00K |
Biora Therapeutics | 4.00K |
LPCN News
- 6 days ago - Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154 - PRNewsWire
- 26 days ago - Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity - PRNewsWire
- 5 weeks ago - Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis - PRNewsWire
- 6 weeks ago - Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154 - PRNewsWire
- 2 months ago - Lipocine Announces Financial Results for the Full Year Ended December 31, 2023 - PRNewsWire
- 2 months ago - Lipocine to Present at 36th Annual Roth Conference - PRNewsWire
- 3 months ago - Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154 - PRNewsWire
- 3 months ago - Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals - PRNewsWire